Sales of a new hepatitisC drug helped boost Johnson  Johnsons secondquarter revenue by  but executives said they dont expect the pills sales to keep pace and outlined several challenges facing the overall healthcare market Sales of the hepatitisC pill called Olysio reached  million worldwide in the second quarter compared with  million in the first quarter Olysio
  